Patent ID: 8940902
Filing Date: 2015-01-27
Classification: A61K,A61P,C07D

Abstract:
1. A pharmaceutical composition comprising a compound of formula (IV) wherein: n is 2; R each of which is independently unsubstituted or substituted with 1 or 2 substituents independently selected from the group consisting of alkyl, alkenyl, haloalkyl, Cl, Br, F, I, —CN, —NO 2 , —OR b , —SR b , —S(O)R Z , —S(O) 2 R Z , —NR a R b , —C(O)R b , —C(O)OR b , —C(O)NR a R b , —S(O) 2 NR a R b , —C(═NOH)NH 2 , —C(═NH)NH 2 , —R c , —(CR d R e ) m —CN, —(CR d R e ) m —OR b , —(CR d R e ) m —SR b , —(CR d R e ) m —S(O) 2 R Z , —(CR d R e ) m —NR a R b , —(CR d R e ) m —C(O)R b , —(CR d R e ) m —C(O)OR b , —(CR d R e ) m —S(O) 2 NR a R b , —(CR d R e ) m —R e , —N(R a )—(CR d R e ) m —C(O)R b , —N(R a )—(CR d R e ) m —C(O)OR b , —N(R a )—(CR d R e ) m —C(O)NR a R b , —O—(CR d R e ) m —C(O)R b , —O—(CR d R e ) m —C(O)OR b , and —O—(CR d R e ) m —C(O)NR a R b ; R R R R R R R m is 1; and a pharmaceutically acceptable carrier to treat a disorder of the central nervous system wherein an inhibitor of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme activity is of therapeutic benefit; wherein the disorder is selected from the group comprising decline in cognitive function in Alzheimer's and associated dementias, cognitive deficits associated with aging and neurodegeneration, dementia, senile dementia, AIDS dementia, major depressive disorder, psychotic depression, treatment resistant depression, anxiety, panic disorder, post traumatic stress disorder, depression in Cushing's syndrome, steroid-induced acute psychosis, cognitive deficits associated with diabetes, attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), mild cognitive impairment, and schizophrenia.